文献速递垂体与肾上腺疾病

利伐沙班预防ACTH依赖性库欣综合征血栓的安全性与有效性

Safety and effectiveness of rivaroxaban thromboprophylaxis in adrenocorticotropic hormone-dependent Cushing syndrome.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该单中心回顾性研究纳入70例ACTH依赖性库欣综合征成人患者,比较2019年前后常规口服利伐沙班(10 mg每日一次)预防静脉血栓栓塞(VTE)的效果。结果显示,未预防组VTE发生率为13.8%,而引入利伐沙班后无新发VTE,且未观察到出血并发症,提示该预防策略安全有效。

要点

  • ACTH依赖性库欣综合征患者VTE风险高,常规利伐沙班预防可显著降低VTE发生率。
  • 利伐沙班10 mg每日一次预防未增加出血风险,血液学参数稳定。
  • 建议在诊断时尽早启动利伐沙班预防,并持续至围手术期和术后。

核心结论

  • 在ACTH依赖性库欣综合征患者中,常规口服利伐沙班预防VTE是安全且有效的。
  • 未预防组VTE发生率为13.8%,引入利伐沙班后未发生VTE事件。
  • 利伐沙班预防未观察到重大或轻微出血并发症。

研究设计与样本

  • 单中心回顾性研究,纳入2012年至2025年管理的70例ACTH依赖性库欣综合征成人患者(2019年前29例,2019年后41例)。
  • 比较2019年引入常规利伐沙班预防(10 mg每日一次)前后的VTE发生率。
  • 库欣病是最常见亚型(2019年前26/29,2019年后34/41)。

主要发现

  • 未预防组(2019年前)4例患者(13.8%)发生6次VTE事件,发生于术前和术后。
  • 2019年后队列中,5例患者在内分泌评估前和利伐沙班启动前发生7次VTE事件。
  • 其中2例有复发性VTE且已接受长期治疗剂量抗凝,故41例中39例接受利伐沙班预防。
  • 接受利伐沙班预防的患者中未观察到重大或轻微出血并发症,血液学参数稳定。
  • 所有患者完成规定预防疗程,中位持续时间7.9个月。

关键数值与推荐

  • 利伐沙班预防剂量为10 mg每日一次口服。
  • 未预防组VTE发生率为13.8%(4/29)。
  • 利伐沙班预防中位持续时间为7.9个月。

临床怎么用

  • 对ACTH依赖性库欣综合征患者,应在诊断时尽早启动利伐沙班预防。
  • 预防应持续至围手术期和术后,以覆盖术前和术后VTE风险。
  • 利伐沙班10 mg每日一次预防未增加出血风险,可安全使用。

局限性

  • 回顾性单中心研究,样本量较小(70例)。
  • 2019年后队列中部分VTE事件发生于利伐沙班启动前,可能影响效果评估。
  • 未报告统计学比较结果(如P值)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Adrenocorticotropic hormone (ACTH)-dependent Cushing syndrome (CS) is associated with a markedly increased risk of venous thromboembolism (VTE), yet thromboprophylaxis strategies remain inconsistent across clinical practice. In 2019, our center introduced routine oral rivaroxaban prophylaxis (10 mg once daily) for all patients with ACTH-dependent CS. OBJECTIVE: To evaluate the safety and effectiveness of routine rivaroxaban prophylaxis in ACTH-dependent CS. METHODS: We retrospectively reviewed 70 adults with ACTH-dependent CS managed between 2012 and 2025 (29 pre-2019 and 41 post-2019) to compare VTE incidence before and after the introduction of rivaroxaban. RESULTS: There were no differences in baseline characteristics between the 2 groups. Cushing disease (ie, secondary to a pituitary corticotroph adenoma) was the most common subtype (26/29 pre-2019 and 34/41 post-2019). Among patients without routine prophylaxis (pre-2019), 4 patients (13.8%) developed 6 VTE events, occurring both pre- and postoperatively. In the post-2019 cohort, 5 patients experienced 7 VTE events before endocrine assessment and before rivaroxaban could be initiated. Two had recurrent VTE and were already receiving long-term treatment-dose anticoagulation; therefore, 39 of the 41 proceeded with rivaroxaban prophylaxis. No major or minor bleeding complications were observed. Hematological parameters remained stable, and all patients completed the prescribed prophylaxis course (median duration: 7.9 months). CONCLUSION: In our cohort, VTE incidence was 13.8% without prophylaxis and did not occur after the introduction of routine rivaroxaban. Prophylactic oral rivaroxaban in ACTH-dependent CS was safe and effective in preventing new, recurrent, perioperative, and postoperative VTE events, supporting its early initiation at diagnosis and continuation through the peri- and postoperative period.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Htut Z, Mundhra A, Lazarus K, et al. Safety and effectiveness of rivaroxaban thromboprophylaxis in adrenocorticotropic hormone-dependent Cushing syndrome. J Clin Endocrinol Metab. 2026. PMID: 41540719. doi:10.1210/clinem/dgag014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。